Actylis: Advancing Innovation in Biopharmaceuticals with a Leading Global Biopharma Partner
In the dynamic realm of biopharmaceuticals,
Actylis stands out as a crucial collaborator, consistently offering
forward-thinking solutions to address complex industry challenges. This series
of case studies highlights Actylis’ strategic initiatives and their significant
role in resolving critical manufacturing obstacles in the biopharma sector.
Transforming Concentrated Buffer Production for a Major Biopharma Client
Challenge:
The client required 10× concentrated buffers, representing a substantial shift
from their existing formulation, particularly with respect to pH parameters.
Actylis fine-tuned the formulation’s pH by
precisely adding NaOH or HCl and closely monitoring levels throughout the
process. The R&D phase was fast-tracked, resulting in a successful product
launch within just six weeks.
Benefits:
Partnering with Actylis enabled the client to refine their production process,
meet strict specifications, and accelerate their market launch. The customized
solution not only conserved resources but also strengthened the biopharma
CDMO’s market position.
Resolving Bag Integrity Concerns for a Biopharma Supplier
Challenge:
The biopharma supplier encountered issues with bag integrity due to defective
welding, raising concerns regarding documentation and potential sterility
breaches identified during visual inspection.
Actylis collaborated closely with the
supplier, deploying QA specialists on-site to inspect the bags. Together, the
teams prepared the necessary documentation to release the batches under
comprehensive GMP oversight.
Benefits:
By leveraging Actylis’ expertise and collaborative approach, the supplier
successfully addressed the integrity issues while maintaining product quality
and compliance. Actylis’ transparency and strict adherence to GMP standards
helped build confidence and trust among stakeholders.
Preventing Sample Bag Shortages
Challenge:
A global shortage of single-use bio bags, combined with increasing demand per
commercial batch, placed pressure on supply timelines and production delivery.
Actylis responded by maintaining strategic
buffer stock and placing advance orders for sample bags. Through proactive
planning and strong partner networks, Actylis ensured production continued
without disruption.
Benefits:
Clients benefited from uninterrupted production and minimized delays. Actylis’
reliability and commitment to excellence strengthened client trust and
reinforced long-term working relationships.
Navigating Raw Material Supply Constraints
Challenge:
Surging demand and extended lead times for key raw materials such as Tris,
HEPES, and NaOH created challenges in meeting production schedules.
To mitigate these risks, Actylis leveraged
strong relationships with key suppliers and qualified alternate sources. The
team also worked closely with clients to utilize safety stocks and, when
required, enable direct procurement.
Benefits:
Actylis’ proactive and forward-looking strategy minimized disruptions caused by
raw material shortages, ensuring timely production and fulfilment of client
needs. Transparent communication and strong supplier-client collaboration
further strengthened supply chain resilience.
Looking Ahead
Actylis continues to transform the
biopharmaceutical manufacturing landscape by enabling clients to overcome
challenges and drive innovation forward. With a strong commitment to quality,
compliance, and partnership, Actylis remains a trusted leader shaping the
future of the biopharma industry.
